What enables the safe prescription and monitoring of morphine for chronic breathlessness? Insights from a Normalisation Process Theory-informed implementation survey and interviews with clinicians

BackgroundShortness of breath affects almost 10% of the general population, in particular people with lung or heart disease receiving palliative care. Reducing breathlessness by implementing effective pharmacological and non-pharmacological treatment is vital for relieving this physical and mental suffering in chronic illness. This mixed-methods implementation study (conducted as part of the Morphine and BrEathLessness trial (MABEL) of the clinical effectiveness and safety of regular low-dose oral modified release morphine) investigates how the experiences, attitudes and practices of clinicians affect the implementation of morphine for chronic breathlessness. MethodsMixed-methods survey and interview study with clinicians at participating trial sites, informed by Normalisation Process Theory: O_LILearning Needs Assessment survey to provide early indication of clinicians experiences and knowledge C_LIO_LINormalisation Measurement instrument (NoMAD) survey at two time points to measure extent to which morphine prescribing fitted with current practice C_LIO_LISemi-structured interviews with clinicians to explore perspectives about safe morphine use. C_LI ResultsParticipants: Learning Needs Assessment (n=75, Doctors 43%, Nurses 51%, Other/not stated 6%), NoMAD 1 (n=64; Doctors 45%, Nurses 50%, Other 5%), NoMAD 2 (n=27; Doctors 41%, Nurses 52%, Other 9%), interviews (n=8, Doctors n=5, Nurses n=3). Learning Needs Assessment: two-thirds agreed they had learning needs about use of morphine for breathlessness. NoMAD surveys: 92% viewed morphine for breathlessness as a legitimate part of their role, but only 36% thought sufficient training about its use was provided. 81% stated they could integrate the use of morphine for breathlessness into their existing work, but only 39% had confidence in colleagues to do so. Interviews supported NoMAD findings and provided a richer understanding of how communication and co-ordination across settings and specialisms underpinned implementation. ConclusionsClinicians accept that morphine prescription for breathlessness management is a legitimate part of their role and are keen to improve their practice, but lack of training, resources, and confidence in the skills of others are barriers to implementation. Consistent communication about, and with, patients across settings and specialisms can enable the delivery of a safe, effective approach that enables patients to knowledgably take part in shared decision-making about the use of morphine for breathlessness. Trial registrationISRCTN87329095 (Registered 25/02/2019), EudraCT 2019-002479-33